The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Vertex Pharmaceuticals, Inc shares valued at $3,895,768 were purchased by Kewalramani Reshma on Aug 06 ’25. At $389.58 per share, Kewalramani Reshma acquired 10,000 shares. The insider’s holdings grew to 115,968 shares worth approximately $45.26 million following the completion of this transaction.
Also, SACHS BRUCE I purchased 5,000 shares, netting a total of over 1,948,416 in proceeds. Following the buying of shares at $389.68 each, the insider now holds 45,000 shares.
Before that, LR 2019 Benefit Trust had added 170 shares to its account. In a trade valued at $76,021, the Director bought Vertex Pharmaceuticals, Inc shares for $447.18 each.
As published in a research note from Wells Fargo on August 06, 2025, Vertex Pharmaceuticals, Inc [VRTX] has been rated up from an Equal weight to an Overweight and the price target has been revised to $460. Analysts at Wolfe Research downgraded the stock from ‘”an Outperform”‘ to ‘”a Peer perform”‘ outlook in a report released in early May. As of May 06, 2025, Leerink Partners has decreased its “an Outperform” rating to a “Market perform” for VRTX.
Analyzing VRTX Stock Performance
On last trading session, Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] plunged -1.42% to $390.3. The stock’s lowest price that day was $388.71, but it reached a high of $395.589 in the same session. During the last five days, there has been a surge of approximately 3.91%. Over the course of the year, Vertex Pharmaceuticals, Inc shares have dropped approximately -15.98%. Shares of the company reached a 52-week high of $519.68 on 03/14/25 and a 52-week low of $362.50 on 08/11/25.
Support And Resistance Levels for Vertex Pharmaceuticals, Inc (VRTX)
According to the 24-hour chart, there is a support level at 387.48, which, if violated, would cause prices to drop to 384.65. In the upper region, resistance lies at 394.36. The next price resistance is at 398.41. RSI (Relative Strength Index) is 37.34 on the 14-day chart, showing neutral technical sentiment.
Is Vertex Pharmaceuticals, Inc subject to short interest?
Stocks of Vertex Pharmaceuticals, Inc saw a sharp steep in short interest on 2025-07-31 dropping by 27251.0 shares to 4.36 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 4.39 million shares. A decline of -0.62% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.04 of the overall float, the days-to-cover ratio (short ratio) decline to 4.04.
Which companies own the most shares of Vertex Pharmaceuticals, Inc (VRTX)?
In terms of Vertex Pharmaceuticals, Inc share price expectations, FactSet research, analysts set an average price target of 478 in the next 12 months, up nearly 20.73% from the previous closing price of $395.92. Analysts anticipate Vertex Pharmaceuticals, Inc stock to reach 553 by 2025, with the lowest price target being 420. In spite of this, 16 analysts ranked Vertex Pharmaceuticals, Inc stock as Buy at the end of 2025. On February 12, 2025, Canaccord Genuity assigned a price target of “a Hold” to the stock and upgraded coverage with a $424.
